On November 7, Arkuda Therapeutics announced the completion of a $44 million Series A round of financing, led by Atlas Venture and Pfizer Ventures, and Tekla Capital Management and BioInnovation Capital. The company will use the funds to promote its treatment of frontotemporal dementia (FTD) drugs through Phase I… Continue Reading Targeting granule protein precursors to prevent dementia, this company is spotlighted by Pfizer

  Prostate cancer is a male androgen-dependent tumor. Androgen stimulates the growth of prostate cancer cells and induces disease progression. Metastatic prostatectomy (ADT) is commonly used in patients with metastatic prostate cancer. The initial response rate can reach 80%-90%, but almost all patients will eventually progress to metastatic castration-resistant prostate… Continue Reading Competition pattern of new drug development in advanced prostate cancer

  Chronic atrophic gastritis (CAG) refers to the localization of the gastric mucosa, extensive glandular reduction, atrophy and thinning of the mucosa. Chronic atrophic gastritis has no specific symptoms, high recurrence rate, and is associated with certain gastric cancer risk and is not easy to cure. How to treat chronic… Continue Reading How to treat chronic atrophic gastritis?

  I. Introduction   Histamine was first discovered in the last century. It is the main medium for many biological reactions including allergic reactions. Some of these biological reactions are involved in the pathophysiological processes of common skin diseases. In theory, there are three ways to block the biological effects… Continue Reading Antihistamines for itch treatment

  Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.

  Lupus erythematosus (LE) is a typical autoimmune connective tissue disease and a disease-causing disease. One end of the spectrum is cutaneous lupus erythematosus (CLE), the lesion is mainly confined to the skin; the other end is systemic lupus erythematosus (SLE), in addition to skin damage, the lesion involves multiple… Continue Reading Pathogenesis of skin-type lupus erythematosus and analysis of 9 new treatments

  From the discovery of tubulin to the approval of vinblastine for anticancer treatment, it has been more than half a century. Microtubules play an extremely important role in cell division, and disruption of the formation of mitotic spindles affects all dividing cells. For cancer cells that proliferate faster than… Continue Reading The development of microtubule inhibitors – the big story of small molecules

  On July 31, Merck announced that the FDA approved Keytruda monotherapy for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma who had previously received at least one line of systemic PD-L1 expression (CPS ≥ 10). This approval is based primarily on data from two studies. One… Continue Reading Keytruda new indications approved, the first esophageal cancer PD-1 therapy

  I. Penicillins Penicillin can be divided into: narrow-spectrum penicillin, penicillin-resistant penicillin, broad-spectrum penicillin against Enterobacter, and broad-spectrum penicillin against Pseudomonas aeruginosa. Narrow-spectrum penicillin: penicillin G, procaine penicillin, benzathine penicillin, penicillin V, etc., mainly acting on penicillin of Gram-positive bacteria Penicillin-resistant penicillin: oxacillin, cloxacillin, flucloxacillin, etc., antibacterial spectrum similar to… Continue Reading Antibacterial spectrum of antibacterial drugs